

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/03698 A1

(51) International Patent Classification⁷: **A61K 31/5383**,
9/00, 9/50

(21) International Application Number: PCT/US00/16969

(22) International Filing Date: 21 June 2000 (21.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/143,019 9 July 1999 (09.07.1999) US

(71) Applicant: **ORTHO-MCNEIL PHARMACEUTICAL, INC.** [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).

(72) Inventors: **YU, Danny**; P.O. Box 1015, Somerville, NJ 08876 (US). **ROCHE, Edward**; 1849 Hawthorne Place, Poli, PA 19301 (US).

(74) Agents: **CIAMPORCERO, Audley, A., Jr.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TASTE MASKED PHARMACEUTICAL LIQUID FORMULATIONS

(57) Abstract: A liquid composition for oral administration comprising a pharmaceutically active medicament coated with a taste masking effective amount of a polymer blend of (a) dimethylaminoethyl methacrylate and neutral methacrylic acid ester (MM/MAE) and (b) a cellulose ester, in an aqueous vehicle, wherein the polymer weight ratio of the cellulose ester to the MM/MAE is about 40:60 to about 90:10, preferably about 60:40. The liquid composition utilizes a "reverse enteric coating" which is soluble in the acid pH's of the stomach, generally about 1.0 to 4.0, but relatively insoluble at the non-acidic pH's of the mouth. The coatings provide for rapid release and absorption of the drug, which is generally desirable in the case of liquid dosage forms.



WO 01/03698 A1

TASTE MASKED PHARMACEUTICAL LIQUID FORMULATIONS

FIELD OF THE INVENTION

5 This invention relates to oral pharmaceutical liquid formulations which effectively mask the unpleasant taste of pharmaceuticals or nutritional supplements with bitter or otherwise undesirable taste characteristics. More specifically, the invention relates to liquid suspensions of reverse enteric polymer coated dosage forms that mask the unpleasant taste of the active
10 agent. The liquid suspensions may be swallowed without producing a bitter taste in the mouth, but the coated agent is immediately bioavailable upon exposure to the pH levels found in the stomach.

BACKGROUND OF THE INVENTION

15 Medicaments can be administered to the patient in many forms with oral administration being the most popular. Medicaments can be given to the patient orally as liquid solutions, emulsions, or suspensions, or in solid form such as capsules or tablets. Infants, children, older persons, and many other
20 persons are unable to swallow whole tablets and capsules. Therefore, in cases where the dosage to be administered cannot be made into a very small tablet or capsule, it is desirable to provide the medicine in liquid or chewable form.

25 Many active ingredients, such as antibiotics, possess a strong, unpleasant taste. When a medicament is formulated as a tablet or capsule intended to be swallowed whole, the taste of the active ingredient is usually not an issue since the capsule keeps the active ingredient from contacting the mouth and the tablet can be coated to prevent contact of the active with the
30 mouth for the short time the tablet is present in the mouth. In contrast, masking of the unpleasant taste characteristics of the active agent is an extremely important factor in the formulation of liquid and chewable

pharmaceuticals. The palatability of the liquid or chewable dosage form is a critical factor in ensuring patient compliance.

In some cases, the unpleasant taste of the active medicament in a
5 liquid or chewable formulation can be overpowered by adding flavoring
ingredients and sweeteners to improve taste and palatability. However, where
the active medicament possesses a particularly strong or bitter taste, such as
is the case with many antibiotics, the mere addition of such flavoring
ingredients and sweeteners is insufficient to improve taste and palatability.
10 Accordingly, various taste masked coating compositions have been employed
in the formulation of liquid suspension and chewable tablet dosage forms.

U.S. patent 5,599,556 discloses liquid formulations where the active
ingredient is coated with a single outer polymeric coating derived from
15 prolamine cereal grain proteins and a plasticizing agent. The coatings are
designed to rapidly degrade once the composition leaves the mouth.

U.S. patent 5,489,436 discloses chewable tablets made from a coated
medicament where the coating is a "reverse enteric coating" designed to be
20 soluble at the lower pH of the stomach but relatively water insoluble at the
higher pH's of the mouth. The coatings are comprised of a polymer blend of
dimethylaminoethyl methacrylate and neutral methacrylic acid ester and a
cellulose ester.

25 While the above mentioned reverse enteric coating method of taste
masking oral formulations are disclosed in connection with chewable tablets,
there is no disclosure of their use in a liquid formulation, where the taste
masking coating will need to survive in an aqueous environment for an
extended period. There is thus a need for a taste masking formulation
30 suitable for an aqueous liquid suspension which is stable and retains its taste
masking properties in the aqueous environment over an extended period, yet
which exhibits immediate bioavailability after swallowing and ingestion.

SUMMARY OF THE INVENTION

The present invention provides a liquid composition for oral
5 administration comprising a pharmaceutically active medicament coated with
a taste masking effective amount of a polymer blend of (a)
dimethylaminoethyl methacrylate and neutral methacrylic acid ester
(MM/MAE) and (b) a cellulose ester, in an aqueous vehicle, wherein the
polymer weight ratio of the cellulose ester to the MM/MAE is about 40:60 to
10 about 90:10, preferably about 60:40. The liquid composition utilizes a "reverse
enteric coating" which is soluble in the acid pH's of the stomach, generally
about 1.0 to 4.0, but relatively insoluble at the non-acidic pH's of the mouth.
The coatings provide for rapid release and absorption of the drug, which is
generally desirable in the case of liquid dosage forms.

15

In preferred embodiments the active medicament useful in the taste
masked liquid formulations of the present invention are antibiotic drugs,
particularly levofloxacin, ofloxacin and related quinolone antibiotics, as well as
other known antibiotics which have an unpleasant taste and are formulated
20 for oral liquid administration like cephalosporins, macrolide antibiotics,
penicillins and the like. Other active medicaments which may be beneficially
employed in the liquid compositions of the invention include analgesic drugs,
such as tramadol or codeine, anti-inflammatory drugs such as ibuprofen,
naproxen and other NSAID's . Other active agents which for which the liquid
25 compositions of the invention may be employed include gastro-intestinal
drugs, antihistamines, decongestants, anti-depressants, anti-psychotics,
antivirals, oncolytics, vaccines, antiepileptics (e.g. topiramate), anti-asthma
compounds, antispasmodics, and the like.

30 In accordance with the invention, the particles of active medicament
are generally spray coated with the polymer coating either directly or after
granulation, and then the coated particles are admixed with other

pharmaceutically acceptable additives such as sweeteners, flavorings and the like in an aqueous liquid vehicle for oral administration.

The invention also relates to a method of taste masking medicaments
5 for oral liquid administration by utilizing the coating compositions of the invention.

DETAILED DESCRIPTION

10 The invention relates in particular to taste masked liquid preparations for oral administration comprising a pharmaceutically active medicament having an unpleasant taste which is coated with a reverse enteric coating. Reverse enteric coatings are those which are not water soluble at non-acidic pH's as are present in the mouth, but are soluble in the acid pH levels of the
15 stomach. The coatings provide a protective layer which masks the unpleasant taste characteristics of the active ingredient in the mouth because of its low solubility therein but are readily soluble in the stomach and therefore provide immediate release of the active medicament in the stomach. The reverse enteric coatings encapsulate the active ingredient and thereby effectively and
20 stably mask the taste of the active medicament.

In accordance with the invention, there is provided an orally consumable liquid composition comprising a pharmaceutically active agent in particle form contained in a liquid suspension having a pH greater than about
25 6.0, each particle comprising a core of pharmaceutically active agent, optionally associated with inactive pharmaceutical adjuvants; the core being coated with a taste masking effective amount of a polymer blend of (a) dimethylaminoethyl methacrylate and neutral methacrylic acid ester (MM/MAE) and (b) a cellulose ester, in an aqueous vehicle, wherein the
30 polymer weight ratio of the cellulose ester to the MM/MAE is about 60:40 to about 70:30, preferably about 60:40. In a preferred embodiment, the formulation is prepared as a dry powder which is reconstituted with water to

form the liquid compositions of the invention.

The details of the polymer blend used for the coatings and the coating techniques are described in U.S. patent 5,489,436, hereby incorporated by
5 reference into the present application. In general, the cellulose acetate component, the solubility of which is pH independent, and the MM/MAE component, the solubility of which is pH dependent, are mixed in a ratio which provides the desired diffusion characteristics. The diffusion and solubility of the coating depends on the ratio of the two components and the
10 physicochemical properties of the drug being coated. For the liquid formulations of the present invention, the inventors have found that the optimal ratio of CE:MM/MAE, particularly where the active agent is the quinolone antibiotic levofloxacin, is about 60:40 to 70:30, respectively. This ratio provides the desired diffusion characteristics, i.e. appropriate taste
15 masking while present in the mouth but immediate disintegration and diffusion of the active agent when present at the acidic pH levels of the stomach. The diffusion characteristics thus obtained provides the appropriate immediate bioavailability of the active agent as is generally desirable in a liquid formulation.

20

If necessary, the particles of active agent are first granulated prior to coating, particularly if the particles are irregularly shaped and sized. Preferably, the particles to be coated will be in the range of about 3 to about 500 microns. The optimum thickness of the coating material applied to the
25 particles will depend on the physicochemical characteristics of the active agent but is generally from about 40% to about 120% of applied film. The most preferred level of coating is between about 50% to about 120% by weight of coating to weight of the encapsulated active agent particles. For levofloxacin, the preferred coating level is from about 90% to about 120%,
30 most preferably about 111% initial weight of the particles.

The ingredients for the polymer coating are as disclosed in U.S. Patent

5,489,436. A variety of cellulose esters may be employed in the polymer coating. The preferred cellulose esters are cellulose acetate, cellulose acetate butyrate and cellulose triacetate, with cellulose acetate being most preferred. The preferred MM/MAE is the polymer blend sold under the tradename
5 EUDRAGIT® E-100, available from Rohm Pharma. It is a copolymer based on dimethylaminoethyl methacrylates and neutral methacrylic acid esters with a mean molecular weight of 150,000. Other optional additives such as polyvinylpyrrolidone or 2 vinyl pyridine(V)/styrene(S) copolymer may be added to the polymer blend coating.

10

The preparation of the formulation may be accomplished by a variety of coating techniques known in the art including fluidized bed coating, conventional top spray coating and wet granulation techniques. Preferably, fluidized bed coating with a Wurster column insert is used to apply the
15 coating. In this procedure, the particles of active agent to be coated are suspended in an apparatus that creates an upward stream of air in which the particles move. The stream passes through an area of finely atomized coating material which causes the passing particles to be coated, after which the coated particles move upward through the Wurster column and then travel
20 downward in a fluidized condition countercurrent to a flow of heated fluidized gas whereupon they are dried. The particles may reenter the upward stream for further coating.

Generally, the polymer coating material is dissolved in an organic
25 solvent to make a solution for use in the fluidized bed coating process. A variety of organic solvents may be used, preferably acetone or an acetone methanol mix. The solvent is removed in the drying process and is thus not present in the final composition. The total polymer concentration in the coating solutions can vary, generally in the range of about 5 to about 20% by
30 weight, preferably about 12% w/w.

Once the dried coated particles are obtained, the coated particles are

admixed with other pharmaceutically acceptable adjuvants such as flavorings, sweeteners, thickening agents, colorings and the like to form the compositions of the invention for oral liquid administration. Suitable flavorants include fruit flavors, peppermint, licorice or bubble gum flavors. The
5 sweetening agents may be for example bulk sweeteners such as sucrose or polyols (e.g. maltitol, sorbitol) and/or intense sweeteners such as saccharin, aspartame or acesulfame K. The preparation can be formed as a liquid, or as a powder for reconstitution with water by the pharmacist prior to dispensing.

10 It is also desirable to include an alkalizing agent in the aqueous liquid suspension to maintain the integrity of the reverse enteric taste masked coating. The alkalizing agents that are applicable for use in the present invention are those which are alkaline in aqueous solution and are capable of raising and maintaining the pH of the aqueous suspension above about 5.

15 The alkalizing agent may be selected from any of the following compounds: alkali metal hydroxides, phosphates, carbonates and bicarbonates, such as sodium bicarbonate; magnesium hydroxide; magnesium oxide; magnesium phosphates; magnesium carbonate; magnesium hydroxide carbonate; magnesium glycinate; magnesium silicates; magnesium aluminum silicate;
20 alkaline clays such as bentonite; zeolites; calcium oxide; calcium hydroxide; calcium phosphates; magaldrate; hydrotalcite; dihydroxyaluminum sodium carbonate; ammonium hydroxide; ammonium bicarbonate; ammonium carbonate; ethanolamine; diethanolamine; triethanolamine; tetrasodium ethylenediaminetetraacetic acid, its hydrates and the like. In the case of
25 levofloxacin, sodium bicarbonate is preferred. One or more of such alkalizing agents may be used in an amount to raise the pH of the suspension above 5.0.

As stated, the taste masking formulations of the present invention
30 satisfy the unique requirements of a liquid formulation. In accordance with the invention, there is provided a formulation which is stable, i.e. the taste masking properties survive in a "hostile" aqueous environment after

reconstitution for at least the duration of the treatment period (in the case of antibiotics, 7-14 days), while still providing appropriate taste masking when the product is administered.

5 In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that these examples are intended only to be illustrations without serving as a limitation on the scope of the present invention.

10

EXAMPLE 1

Preparation of Taste Masked Levofloxacin Composition for Oral Liquid Administration

To pharmaceutically active core particles of a coating solution of
15 polymers as described below in Table 1 is prepared by adding the polymers to the acetone .

Table 1: Quantitative Composition of Coated Levofloxacin Beads

Component	% w/w
Levofloxacin	9.836
Eudragit E100	4.328
Cellulose Acetate, NF (CA 398-10)	6.492
Acetone, NF ^a	79.344
Total:	100.0

^a Acetone is removed during process and does not appear in the final product

20 The coating was performed in a Glatt GPCG-3 fluidized bed coater with a 7" Wurster Insert. The polymer weight ratio of Cellulose Acetate to Eudragit E100 in the taste mask coating for the two batches were 60:40 and 70:30 for batches 1 and 2, respectively. The actual coating level, calculated from potency assay, were 111% and 93% of initial respectively. The coating
25 parameters and sieve analysis for the two batches are summarized in Tables 2 and 3.

Table 2: Coating Parameters of the Two Batches of Coated Levofloxacin Beads Manufactured using Glatt GPCG-3 coater with 7" Wurster

Batch	Temperature During Spraying			Fluidiza- tion	Nozzle Size (mm)	Atomization Air (bar)	Partition Height (inch)	Spray Rate (g/min)	Spray Time (min)	Drying Time (min)	Product Drying Temp (°C)	Gross Yield (%)
	Batch	Inlet (°C)	Product (°C)	Exhaust (°C)								
1	1.2	62-64	25-40	26-31	12	1.2	3	1	16.8- 25.7	183	30	30-42 °C 88.5
2	1.1	57-64	30-33	26-32	12	1.2	3	1	16.6- 25.3	159	30	30-36 °C 87.4

Table 3: Sieve Analysis of Coated Levofloxacin

Batch	1		2	
	1		2	
Mesh Size	1		2	
>40	0.44		0.43	
40-60	5.61		2.81	
60-80	18.36		14.68	
80-100	14.81		15.01	
100-140	35.29		44.14	
140-200	19.59		16.73	
<200	5.91		6.20	
Total	100.0		100.0	

Following coating of the levofloxacin particles, the coated particles are admixed with the adjuvants set forth in the following Table 4 to form a liquid composition for oral administration suitable for pediatric use.

5

Table 4: Quantitative Composition of Levofloxacin Powder for Reconstitution
125 and 250 mg/5mL when reconstituted

Component	g/5mL	g/5mL
Levofloxacin	0.125 ^a	0.250 ^a
Eudragit E100	0.05 ^a	0.10 ^a
Cellulose Acetate, NF (CA 398-10)	0.075 ^a	0.15 ^a
Sodium Bicarbonate, USP	0.02	0.02
Microcrystalline Cellulose + Carboxymethyl Cellulose, NF (Avicel RC591)	0.275	0.275
Sucrose, NF (Baker's Special Granulated)	2.5	2.5
N&A Bubblegum Flavor	0.001	---
N&A Fruit Punch Flavor	---	0.0075
FD&C Red #40	0.00015	0.002
Water qs ad	5.0 mL ^b	5.0 mL ^b

^a Based on theoretical coating level of 100% initial. Actual amount depends on the assay potency of the coated levofloxacin beads used in the batch.

^b Water to be added by pharmacist before dispensing.

EXAMPLE 2

Dissolution Studies of Taste Masked Levofloxacin Composition for Oral Liquid Administration

10

The reverse enteric coated levofloxacin particles, prepared as described in Example 1 were tested using a dissolution apparatus. Dissolution studies were conducted at pHs 1.2, 3 and 7.5 for the two batches of coated levofloxacin beads prepared as described in Example 1. The results, as summarized in Table 5, demonstrate that very little active agent is released at pH 7.5, while rapid release was observed at pH 1.2.

15

Table 5: Dissolution of Taste Masking Formulations

Batch No.	Theoretical Coating (% initial)	Dosage Form	Dissolution Medium (900 mL)	pH	Dose / Vessel (mg)	Percent Dissolved at						
						10 min	20 min	30 min	45 min	60 min	90 min	120 min
1	88 (111% actual)	Coated Levo Beads 250 mg levo equivalent	0.1N HCl 900mL + 0.1% Tween 20	1.2	250	93.75	95.07	95.07	95.25	95.70	94.53	95.00
1	88 (111% actual)	Coated Levo Beads 250 mg levo equivalent	0.05M KH ₂ PO ₄ /citric acid buffer 900mL + 0.1% Tween 20	3.0	250	47.72	80.77	94.02	98.84	99.59	99.74	99.65
1	88 (111% actual)	Coated Levo Beads 250 mg levo equivalent	0.05M KH ₂ PO ₄ /NaOH buffer 900mL + 0.1% Tween 20	7.5	250	2.81	3.23	3.42	3.68	3.92	4.28	4.81
2	76 (93% actual)	Coated Levo Beads 250 mg levo equivalent	0.1N HCl 900mL + 0.1% Tween 20	1.2	250	90.64	99.43	100.83	99.77	100.64	99.40	101.25
2	76 (93% actual)	Coated Levo Beads 250 mg levo equivalent	0.05M KH ₂ PO ₄ /citric acid buffer 900mL + 0.1% Tween 20	3.0	250	18.66	27.32	35.38	46.98	56.94	75.98	89.01
2	76 (93% actual)	Coated Levo Beads 250 mg levo equivalent	0.05M KH ₂ PO ₄ /NaOH buffer 900mL + 0.1% Tween 20	7.5	250	3.22	3.71	4.06	4.81	5.30	6.20	7.08

Data for Information Only

Claims

We claim:

- 5 1. An orally consumable liquid composition comprising a pharmaceutically active agent in particle form contained in a liquid suspension having a pH greater than about 6.0, each particle comprising a core of pharmaceutically active agent, optionally associated with inactive pharmaceutical adjuvants; the core being coated with a taste masking effective amount of a polymer
10 blend of (a) dimethylaminoethyl methacrylate and neutral methacrylic acid ester (MM/MAE) and (b) a cellulose ester, in an aqueous vehicle, wherein the polymer weight ratio of the cellulose ester to the MM/MAE is about 40:60 to about 90:10.
- 15 2. The orally consumable liquid composition of claim 1 wherein the level of coating on the particle is between about 40% to about 120% by weight of coating to weight of the encapsulated active agent particles.
3. The orally consumable liquid of claim 1 wherein the polymer weight ratio of
20 the cellulose ester to the MM/MAE is about 60:40.
4. The orally consumable liquid of claim 1 wherein the cellulose ester is selected from cellulose acetate, cellulose acetate butyrate and cellulose triacetate.
- 25 5. The orally consumable liquid of claim 1 wherein the active agent is selected from antibiotic drugs, analgesic drugs, anti-inflammatory drugs, gastro-intestinal drugs, antihistamines, decongestants, anti-depressants, anti-psychotics, antivirals, oncolytics, vaccines, antiepileptics, ant-asthma drugs,
30 and antispasmodics.

6. The orally consumable liquid of claim 1 wherein the coated active agent particles are admixed with one or more pharmaceutically acceptable adjuvants.
7. The orally consumable liquid of claim 1 wherein the coated active agent particles are admixed with an alkalizing agent.
8. The orally consumable liquid of claim 1 wherein the active agent is levofloxacin.
9. The orally consumable liquid composition of claim 6 wherein the cellulose ester is cellulose acetate and the MM/MAE polymer is EUDRAGIT 100 and wherein the ratio of the cellulose acetate to the EUDRAGIT 100 is about 60:40 to about 70:30.
10. The orally consumable liquid of claim 8 wherein the polymer weight ratio is about 60/40.
11. The orally consumable liquid of claim 8 wherein the coating level is from about 90% to about 120% of the initial weight of the particles.
12. The orally consumable liquid of claim 8 wherein the coating level is 111% of the initial weight of the particles.
13. The orally consumable liquid of claim 8 wherein the coated levofloxacin particles are admixed with one or more pharmaceutically acceptable adjuvants.
14. The orally consumable liquid of claim 8 wherein the coated levofloxacin particles are admixed with an alkalizing agent.
15. The orally consumable liquid of claim 14 where the alkalizing agent is sodium bicarbonate.

16. The orally consumable liquid of claim 13 wherein the adjuvants are selected from flavorings, sweeteners, thickening agents, and colorings.

17. The orally consumable liquid of claim 13 selected from those having the
5 following formula:

Component	g/5mL	g/5mL
Levofloxacin	0.125 ^a	0.250 ^a
Eudragit E100	0.05 ^a	0.10 ^a
Cellulose Acetate, NF	0.075 ^a	0.15 ^a
Sodium Bicarbonate, USP	0.02	0.02
Microcrystalline Cellulose + Carboxymethyl Cellulose, NF (Avicel RC591)	0.275	0.275
Sucrose, NF (Baker's Special Granulated)	2.5	2.5
N&A Bubblegum Flavor	0.001	---
N&A Fruit Punch Flavor	---	0.0075
FD&C Red #40	0.00015	0.002
Water qs ad	5.0 mL	5.0 mL

INTERNATIONAL SEARCH REPORT

Internatic	Application No
PCT/US 00/16969	

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/5383 A61K9/00 A61K9/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 551 820 A (BAYER AG) 21 July 1993 (1993-07-21) claims examples ---	1-17
A	DATABASE WPI Section Ch, Week 198745 Derwent Publications Ltd., London, GB; Class A96, AN 1987-318176 XP002155520 & JP 62 226926 A (TEISAN SEIYAKU KK), 5 October 1987 (1987-10-05) abstract --- -/--	1-6, 8-13,16, 17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

15 December 2000

Date of mailing of the international search report

27/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

Internatic	Application No
PCT/US 00/16969	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category ~	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 470 667 A (MERCK, SHARP &DOHME-CHIBRET) 12 February 1992 (1992-02-12) claims examples ----	1,5-8, 13,14,17
A	EP 0 523 847 A (MCNEIL-PPC INC., U.S.A.) 20 January 1993 (1993-01-20) cited in the application claims ----	1-6,9
A	WO 94 04505 A (BOUCHARA) 3 March 1994 (1994-03-03) claims 1,15 example 3 page 11, line 1 - line 2 -----	1,5-8, 13,14,17

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatic Application No

PCT/US 00/16969

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 551820 A	21-07-1993	DE 4200821 A AT 186212 T AU 670763 B AU 3113893 A CA 2087146 A CN 1074603 A,B CZ 283787 B DE 59309858 D DK 551820 T ES 2141117 T GR 3032382 T HU 64693 A HU 211154 B IL 104362 A JP 5255072 A MX 9207630 A NZ 245658 A PL 175569 B RU 2110255 C SK 372092 A US 5695784 A US 6136347 A ZA 9300234 A	22-07-1993 15-11-1999 01-08-1996 22-07-1993 16-07-1993 28-07-1993 17-06-1998 09-12-1999 25-04-2000 16-03-2000 27-04-2000 28-02-1994 30-10-1995 15-04-1997 05-10-1993 30-07-1993 24-02-1995 29-01-1999 10-05-1998 10-05-1995 09-12-1997 24-10-2000 16-08-1993
JP 62226926 A	05-10-1987	NONE	
EP 470667 A	12-02-1992	FR 2665635 A CA 2048300 A DE 69115590 D DE 69115590 T JP 4230631 A JP 6080012 B US 5304559 A	14-02-1992 11-02-1992 01-02-1996 01-08-1996 19-08-1992 12-10-1994 19-04-1994
EP 523847 A	20-01-1993	CA 2068402 A,C DE 69210124 D DE 69210124 T ES 2089403 T US 5489436 A	15-12-1992 30-05-1996 02-10-1996 01-10-1996 06-02-1996
WO 9404505 A	03-03-1994	FR 2694751 A	18-02-1994